NCT00637234View on ClinicalTrials.gov

Oxcarbazepine as an Adjunct of Antipsychotic Therapy in Acute Schizophrenia

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

April 30, 2008

Study Completion Date

July 31, 2008

Conditions
Schizophrenia
Interventions
DRUG

Oxcarbazepine

Oxcarbazepine (OXC), 300 mg tablets, up to 600 mg three times daily

DRUG

Placebo

Placebo, 300 mg tablets, up to 600 mg three times daily

Trial Locations (2)

50924

University of Cologne, Dept. of Psychiatry and Psychotherapy, Cologne

84416

Isar-Amper-Klinikum gemeinnützige GmbH, Klinik Taufkirchen (Vils), Taufkirchen (Vils)

All Listed Sponsors
lead

University of Cologne

OTHER

NCT00637234 - Oxcarbazepine as an Adjunct of Antipsychotic Therapy in Acute Schizophrenia | Biotech Hunter | Biotech Hunter